Combined proteasome and histone deacetylase inhibition: A promising synergy for patients with relapsed/refractory multiple myeloma

Leuk Res. 2010 Sep;34(9):1111-8. doi: 10.1016/j.leukres.2010.04.001. Epub 2010 May 15.


Multiple myeloma (MM) is an incurable disease characterized by the accumulation of malignant plasma cells in the bone marrow. Recently, an improved understanding of the biology of the disease has led to the development of targeted agents such as the proteasome inhibitor bortezomib and the immunomodulatory agents thalidomide and lenalidomide; however, MM remains incurable. The combination of bortezomib and an HDAC inhibitor synergistically induces MM cell apoptosis and may be of value in the treatment of patients with relapsed/refractory MM. This review examines the potential of combined proteasome and HDAC inhibition in the treatment of relapsed/refractory MM.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • Boronic Acids / therapeutic use
  • Bortezomib
  • Drug Synergism
  • Histone Deacetylase Inhibitors / therapeutic use*
  • Humans
  • Lenalidomide
  • Multiple Myeloma / drug therapy*
  • Multiple Myeloma / enzymology
  • Multiple Myeloma / pathology
  • Proteasome Inhibitors*
  • Pyrazines / therapeutic use
  • Recurrence
  • Thalidomide / analogs & derivatives
  • Thalidomide / therapeutic use
  • Transcription, Genetic / drug effects


  • Antineoplastic Agents
  • Boronic Acids
  • Histone Deacetylase Inhibitors
  • Proteasome Inhibitors
  • Pyrazines
  • Thalidomide
  • Bortezomib
  • Lenalidomide